Immix Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	17.51	13.44	17.64	0.39	0.73
Cash & Cash Equivalents	17.51	13.44	17.64	0.39	0.73
Cash Growth	30.31%	-23.85%	4411.66%	-46.72%	-
Other Current Assets	2.28	1.46	0.54	0.14	0.2
Total Current Assets	19.79	14.9	18.19	0.53	0.93
Property, Plant & Equipment	0.05	0	0.01	0.01	0.01
Other Long-Term Assets	0.09	0.01	0	0	0
Total Long-Term Assets	0.14	0.01	0.01	0.01	0.01
Total Assets	19.93	14.91	18.19	0.54	0.94
Accounts Payable	3.72	1.27	0.14	0.25	0.25
Current Debt	0	0	0.05	4.1	4.1
Other Current Liabilities	0	0	0.01	0.92	0.24
Total Current Liabilities	3.72	1.27	0.2	5.27	4.59
Other Long-Term Liabilities	0	0.48	0	0	0
Total Long-Term Liabilities	0	0.48	0	0	0
Total Liabilities	3.72	1.75	0.2	5.27	4.59
Total Debt	0	0	0.05	4.1	4.1
Debt Growth	-	-	-98.78%	-	-
Retained Earnings	-53.41	-37.99	-29.76	-5.37	-4.22
Comprehensive Income	0.13	0.09	0.13	0.13	0.07
Shareholders' Equity	16.41	13.16	17.99	-4.73	-3.65
Net Cash / Debt	17.51	13.44	17.59	-3.71	-3.37
Net Cash / Debt Growth	30.31%	-23.63%	-	-	-
Net Cash Per Share	1.01	0.97	4.79	-1.10	-1.00
Working Capital	16.07	13.62	17.98	-4.74	-3.66
Book Value Per Share	0.95	0.95	4.90	-1.40	-1.08

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).